Coronavirus Live Count Map India
remove_red_eye 1149 Views
With input from Dr Monica Vasudev
1151: Early analysis shows 94.5% efficacy for mRNA-1273 vaccine against SARS-CoV-2
DG Alert excerpts:
- An interim review of results from the Phase III COVEtrial revealed that mRNA-1273, an experimental messenger RNA vaccine encoding the stabilized prefusion SARS-CoV-2 spike protein, is safe and effective for prevention of symptomatic COVID-19 in adults.
- The US National Institute of Allergy and Infectious Diseases (NIAID) is co-developing the vaccine candidate. It stated that the vaccine has a statistically significant efficacy rate of 94.5% on the basis of an initial analysis of 95 cases with symptomatic COVID-19.
- Of the 95 cases, 90 were noted in the placebo group and 5 in the vaccinated group.
- Eleven cases of severe COVID-19 were noted from among the total of 95 cases, all of which occurred in the placebo group.
- According to the independent data safety monitoring board, COVE met the statistical criteria pre-specified in the study protocol for efficacy, and the candidate was safe and well-tolerated.
- COVE is looking at mRNA-1273 at a dose of 100 mcg among 30,000 participants in the US, 18 years of age and older. Individuals were randomizedto receive two doses of mRNA-1273, administered 28 days apart, or placebo.
- The primary efficacy endpoint for the trial is the prevention of symptomatic COVID-19 disease,and the key secondary endpoints include prevention of severe COVID-19 disease and prevention of infection by SARS-CoV-2.
1152: 20% Develop Mental Illness Following COVID-19
- A new study has suggested that 1 in 5 COVID-19 patients are diagnosed with a psychiatric disorder, such as anxiety or depression, within 3 months of testing positive.
- The study has also revealed that having a psychiatric disorder independently increases the risk of getting COVID-19.
- Having a psychiatric illness should be in the list of risk factors for COVID-19, says study co-author Maxime Taquet, PhD, University of Oxford.
- The study was published online November 9 in The Lancet Psychiatry.
- The investigators used the TriNetX analytics network, which captured de-identified data from electronic health records of 69.8 million patients from 54 healthcare organizations in the United States. Of these, 62,354 adults were diagnosed with COVID-19 from January 20 through August 1, 2020.
- Within 14 to 90 days after being diagnosed with COVID-19, 5.8% of patients received a first diagnosis of psychiatric illness. Among patients with health problems other than COVID-19, 2.5% to 3.4% of patients received a diagnosis of a psychiatric disorder.
- Older COVID-19 patients had a two- to threefold increased risk for a first dementia diagnosis.
- Some of this excess risk could point to misdiagnosed cases of deliriumor transient cognitive impairment due to reversible cerebral events.
- There appeared to be a bidirectional relationship between mental illness and COVID-19.
- Individuals with a psychiatric diagnosis had a 65% higher likelihood of being diagnosed with COVID-19 in comparison with their counterparts who did not have mental illness, independently of known physical health risk factors for COVID-19.
Dr KK Aggarwal
President CMAAO, HCFI and Past National President IMA